| Original language | English (US) |
|---|---|
| Pages (from-to) | 420-423 |
| Number of pages | 4 |
| Journal | Journal of Clinical Rheumatology |
| Volume | 28 |
| Issue number | 8 |
| DOIs | |
| State | Published - Dec 1 2022 |
ASJC Scopus subject areas
- Rheumatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis : Results Through Week 52 of the GO-ALIVE Study. / Deodhar, Atul; Chakravarty, Soumya D.; Shiff, Natalie J. et al.
In: Journal of Clinical Rheumatology, Vol. 28, No. 8, 01.12.2022, p. 420-423.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis
T2 - Results Through Week 52 of the GO-ALIVE Study
AU - Deodhar, Atul
AU - Chakravarty, Soumya D.
AU - Shiff, Natalie J.
AU - Lo, Kim Hung
AU - Xu, Stephen
AU - Hsia, Elizabeth C.
AU - Danve, Abhijeet
AU - Reveille, John D.
N1 - Funding Information: Medical writing support was provided by Cheryl Jones of Certara Synchrogenix under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med. 2015;163:461-464) and was funded by Janssen Scientific Affairs, LLC. Funding Information: A.De. received consulting fees for participation in advisory boards from AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB; grant/research support from AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. S.D.C. is an employee of Janssen Scientific Affairs, LLC, and is a shareholder of Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. N.J.S. is an employee of Janssen Scientific Affairs, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stocks in Johnson & Johnson, AbbVie, and Gilead. K.H.L. and S.X. are employees of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson. E.C.H. is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stock in Johnson & Johnson. J.D.R. received consulting fees for participation in Advisory Boards from UCB and Eli Lilly and research grant funding from Eli Lilly and Janssen. A Da. received research grants from Novartis and Eli Lilly, and participated on advisory boards for Janssen, AbbVie, Amgen, and Novartis
PY - 2022/12/1
Y1 - 2022/12/1
UR - http://www.scopus.com/inward/record.url?scp=85142918765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142918765&partnerID=8YFLogxK
U2 - 10.1097/RHU.0000000000001857
DO - 10.1097/RHU.0000000000001857
M3 - Article
C2 - 35649533
AN - SCOPUS:85142918765
SN - 1076-1608
VL - 28
SP - 420
EP - 423
JO - Journal of Clinical Rheumatology
JF - Journal of Clinical Rheumatology
IS - 8
ER -